![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
D Rampe, B Wible, D Fedida, RC Dage and AM Brown
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.
Verapamil is an antagonist of L-type Ca2+ channels, and part of its binding site is located in the sixth transmembrane segment (S6) in the fourth repeat of the protein. Verapamil also blocks K+ channels, which are members of the same supergene family as Ca2+ channels. We examined the effects of verapamil on a rapidly activating delayed rectifier K+ channel (designated fHK) cloned from human heart. Verapamil inhibited 86Rb+ efflux from fHK-transfected human embryonic kidney cells with an EC50 of 4.5 x 10(-5) M. Whole-cell patch-clamp experiments revealed that verapamil induced a rapid component of fHK current inactivation but was without effect on activation. The effect was concentration and voltage dependent and was attributed to open channel blockade. The apparent association and dissociation rate constants measured at +50 mV were about 1.65 x 10(5) M-1 sec-1 and 3.48 sec-1, respectively. S6 of fHK has significant homology to that portion of the verapamil binding site identified in Ca2+ channels, and S6 is thought to form part of the inner mouth of K+ channel pores. The data support a role for verapamil as a blocker of the inner pore of voltage-dependent K+ channels in human myocardium.
This article has been cited by other articles:
|
|
 |
|
  S. Moosmang, N. Haider, N. Klugbauer, H. Adelsberger, N. Langwieser, J. Muller, M. Stiess, E. Marais, V. Schulla, L. Lacinova, et al. Role of Hippocampal Cav1.2 Ca2+ Channels in NMDA Receptor-Independent Synaptic Plasticity and Spatial Memory J. Neurosci., October 26, 2005; 25(43): 9883 - 9892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Caballero, R. Gomez, L. Nunez, I. Moreno, J. Tamargo, and E. Delpon Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations Cardiovasc Res, December 1, 2004; 64(3): 457 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choe, Y.-K. Lee, Y.-T. Lee, H. Choe, S.-H. Ko, C.-U. Joo, M.-H. Kim, G.-S. Kim, J.-S. Eun, J.-H. Kim, et al. Papaverine Blocks hKv1.5 Channel Current and Human Atrial Ultrarapid Delayed Rectifier K+ Currents J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 706 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Mason, K. E. Mitchell, Y. Li, M. R. Finley, and L. C. Freeman Molecular Basis of Voltage-Dependent Potassium Currents in Porcine Granulosa Cells Mol. Pharmacol., January 1, 2002; 61(1): 201 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perchenet and O. Clément-Chomienne Characterization of Mibefradil Block of the Human Heart Delayed Rectifier hKv1.5 J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 771 - 778. [Abstract] [Full Text]
|
|
|
|
|
|
L. Yue, J. L. Feng, Z. Wang, and S. Nattel Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes Cardiovasc Res, April 1, 2000; 46(1): 151 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Hogg, C. Trequattrini, L. Catacuzzeno, A. Petris, F. Franciolini, and D. J. Adams Mechanisms of Verapamil Inhibition of Action Potential Firing in Rat Intracardiac Ganglion Neurons J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1502 - 1508. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Zhang, Z. Zhou, Q. Gong, J. C. Makielski, and C. T. January Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels Circ. Res., May 14, 1999; 84(9): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chouabe, M.-D. Drici, G. Romey, J. Barhanin, and M. Lazdunski HERG and KvLQT1/IsK, the Cardiac K+ Channels Involved in Long QT Syndromes, Are Targets for Calcium Channel Blockers Mol. Pharmacol., October 1, 1998; 54(4): 695 - 703. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Zhang and D. Fedida Potassium Channel–Blocking Actions of Nifedipine: A Cause for Morbidity at High Doses? Circulation, May 26, 1998; 97(20): 2098 - 2098. [Full Text]
|
|
|
|
|
|
X. Zhang, J. W. Anderson, and D. Fedida J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1247 - 1256. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. N. Uebele, S. K. England, A. Chaudhary, M. M. Tamkun, and D. J. Snyders Functional Differences in Kv1.5 Currents Expressed in Mammalian Cell Lines Are Due to the Presence of Endogenous Kvbeta2.1 Subunits J. Biol. Chem., February 2, 1996; 271(5): 2406 - 2412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Snyders and S. W. Yeola Determinants of Antiarrhythmic Drug Action : Electrostatic and Hydrophobic Components of Block of the Human Cardiac hKv1.5 Channel Circ. Res., September 1, 1995; 77(3): 575 - 583. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Levitan, R. Gealy, J. S. Trimmer, and K. Takimoto Membrane Depolarization Inhibits Kv1.5 Voltage-gated K[IMAGE] Channel Gene Transcription and Protein Expression in Pituitary Cells J. Biol. Chem., March 17, 1995; 270(11): 6036 - 6041. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
